Drug Trial Radar · NCT06236438
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
167
Actual
Start
Apr 10, 2024
Primary completion
Oct 2031
Study completion Oct 2031
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug) + chemotherapy, budigalimab +chemotherapy, or pembrolizumab +chemotherapy. In Stage 2, there are 2 treatments arms. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab +chemotherapy or placebo in combination with pembrolizumab +chemotherapy. Chemotherapy consists of IV Infused pemetrexed + IV infused cisplatin or IV infused or injected carboplatin. Approximately 840 adult participants will be enrolled in the study across 200 sites worldwide. Stage 1: In cohort 1, participants will receive intravenously (IV) infused livmoniplimab (dose A)+ IV infused budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + IV Infused pemetrexed. In cohort 2, participants will receive livmoniplimab (dose B) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In cohort 3, participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed . In cohort 4, participants will receive IV Infused pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. Stage 2: In arm 1, participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In arm 2, participants will receive IV Infused placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. The estimated study duration is 55 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Conditions
- Non-Small Cell Lung Cancer
Interventions
LivmoniplimabDrug
Intravenously (IV) Infusion
BudigalimabDrug
IV Infusion
PembrolizumabDrug
IV Infusion
PemetrexedDrug
IV Infusion
CisplatinDrug
IV Infusion
CarboplatinDrug
IV Injection
CarboplatinDrug
IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR)Time frame: Up to 21 Months
- Stage 2: Overall Survival (OS)Time frame: Up to 55 Months
Locations
61 sites in 12 countries. Site status is shown where the registry gives one.
UC San Diego Health - Moores Cancer Center /ID# 267782
La Jolla, California
Memorial Hospital West /ID# 262221
Pembroke Pines, Florida
Bond Clinic /ID# 262611
Winter Haven, Florida
University Cancer and Blood Cent /ID# 261824
Athens, Georgia
The University of Chicago Medical Center /ID# 262259
Chicago, Illinois
University of Kansas Medical Center /ID# 263196
Westwood, Kansas
Baptist Health Lexington /ID# 261823
Lexington, Kentucky
Cancer & Hematology Centers of Western Michigan - East /ID# 261826
Grand Rapids, Michigan
Washington University School Of Medicine - Siteman Cancer Center /ID# 262759
St Louis, Missouri
Stony Brook Cancer Center /ID# 261954
Stony Brook, New York
Cone Health Cancer Center /ID# 262583
Greensboro, North Carolina
Oncology Hematology Care, Inc - Blue Ash /ID# 262733
Cincinnati, Ohio
Guthrie Robert Packer Hospital /ID# 262758
Sayre, Pennsylvania
Renovatio clinical /ID# 262000
El Paso, Texas
Houston Methodist Hospital /ID# 262722
Houston, Texas
Texas Oncology - Plano East /ID# 264356
Plano, Texas
Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311
San Antonio, Texas
Renovatio Clinical /ID# 261999
The Woodlands, Texas
Vista Oncology - East Olympia /ID# 262303
Olympia, Washington
Canberra Hospital /ID# 261891
Garran, Australian Capital Territory, Australia
Nepean Hospital /ID# 262157
Kingswood, New South Wales, Australia
Westmead Hospital /ID# 261894
Westmead, New South Wales, Australia
AZ Maria Middelares /ID# 262313
Ghent, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 262338
Liège, Belgium
UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 262557
Namur, Belgium
Universitair Ziekenhuis Antwerpen /ID# 261270
Edegem, Antwerpen, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 261267
Brussels, Brussels Capital, Belgium
Hospital La Louviere Site Jolimont - Helora /ID# 261269
La Louvière, Hainaut, Belgium
Hospital Clinico Universidad De Los Andes /ID# 262665
Santiago, Chile
Centro de Investigacion y Desarrollo Oncologico /ID# 261800
Temuco, Araucania, Chile
Oncored /Id# 261801
Vitacura, Region Metropolitana Santiago, Chile
Fundacion Arturo Lopez Perez /ID# 261700
Providencia, Santiago Metropolitan, Chile
Sociedad Cem-Cancer Spa /Id# 262316
Viña del Mar, Valparaiso, Chile
Assistance Publique Hopitaux de Marseille - Hopital Nord /ID# 261129
Marseille, Bouches-du-Rhone, France
CHU Grenoble - Hopital Michallon /ID# 261131
La Tronche, Isere, France
Institut Curie /ID# 261127
Paris, Paris, France
Hospices Civils de Lyon - Hopital Louis Pradel /ID# 261644
Bron, Rhone, France
Centre Hosp Intercommunal de Creteil /ID# 261130
Créteil, Val-de-Marne, France
Rambam Health Care Campus /ID# 262431
Haifa, Israel
Shaare Zedek Medical Center /ID# 262432
Jerusalem, Jerusalem, Israel
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.